Molecular Partners Dirección

Dirección controles de criterios 2/4

El CEO de Molecular Partners' es Patrick Amstutz , nombrado en Jan 2004, tiene una permanencia de 20.25 años. compensación anual total es CHF1.05M, compuesta por 36.8% salario y 63.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.24% de las acciones de la empresa, por valor de CHF2.40M. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 4 años, respectivamente.

Información clave

Patrick Amstutz

Chief Executive Officer (CEO)

CHF1.0m

Compensación total

Porcentaje del salario del CEO	36.8%
Permanencia del CEO	20.3yrs
Participación del CEO	2.2%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	4.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Patrick Amstutz en comparación con los beneficios de Molecular Partners?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	CHF1m	CHF385k	-CHF62m
Sep 30 2023	n/a	n/a	-CHF60m
Jun 30 2023	n/a	n/a	-CHF62m
Mar 31 2023	n/a	n/a	-CHF50m
Dec 31 2022	CHF1m	CHF383k	CHF118m
Sep 30 2022	n/a	n/a	CHF117m
Jun 30 2022	n/a	n/a	CHF118m
Mar 31 2022	n/a	n/a	CHF106m
Dec 31 2021	CHF1m	CHF380k	-CHF64m
Sep 30 2021	n/a	n/a	-CHF67m
Jun 30 2021	n/a	n/a	-CHF72m
Mar 31 2021	n/a	n/a	-CHF66m
Dec 31 2020	CHF1m	CHF380k	-CHF63m
Sep 30 2020	n/a	n/a	-CHF53m
Jun 30 2020	n/a	n/a	-CHF48m
Mar 31 2020	n/a	n/a	-CHF43m
Dec 31 2019	CHF930k	CHF363k	-CHF36m
Sep 30 2019	n/a	n/a	-CHF37m
Jun 30 2019	n/a	n/a	-CHF38m
Mar 31 2019	n/a	n/a	-CHF38m
Dec 31 2018	CHF909k	CHF346k	-CHF37m
Sep 30 2018	n/a	n/a	-CHF27m
Jun 30 2018	n/a	n/a	-CHF18m
Mar 31 2018	n/a	n/a	-CHF24m
Dec 31 2017	CHF885k	CHF344k	-CHF25m

Compensación vs. Mercado: La compensación total de Patrick($USD1.15M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD345.26K).

Compensación vs. Ingresos: La compensación de Patrick ha aumentado mientras la empresa no es rentable.

CEO

Patrick Amstutz (48 yo)

20.3yrs

Permanencia

CHF1,047,000

Compensación

Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board since 2004. Dr. Amstutz serves...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Patrick Amstutz	Co-Founder	20.3yrs	CHF1.05m	2.22% CHF 2.5m
Michael Stumpp	Co-Founder	20.3yrs	sin datos	2.31% CHF 2.6m
Robert Hendriks	Senior VP of Finance	4.8yrs	sin datos	sin datos
Alexander Zurcher	COO & Member of Management Board	1.8yrs	sin datos	0.077% CHF 86.1k
Renate Gloggner	Executive VP of People & Community and Member of Management Board	2.4yrs	sin datos	0.069% CHF 77.1k
Daniel Steiner	Senior Vice President of Research & Technology	3.2yrs	sin datos	sin datos
Seth Lewis	Senior Vice President of Investor Relations	no data	sin datos	sin datos
Michael Pitzner	General Counsel	1.5yrs	sin datos	sin datos
Pamela Trail	Strategic Consultant	4.8yrs	sin datos	sin datos
Anne Goubier	Senior Vice President of Research & Early Development	2.3yrs	sin datos	sin datos
Philippe Legenne	Interim Chief Medical Officer	less than a year	sin datos	sin datos

2.8yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0QXX se considera experimentado (2.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Patrick Amstutz	Co-Founder	6.6yrs	CHF1.05m	2.22% CHF 2.5m
Steven H. Holtzman	Independent Non Executive Director	10yrs	CHF135.00k	0.044% CHF 49.3k
William A. Burns	Independent Chairman of the Board	6.6yrs	CHF295.00k	0.081% CHF 90.3k
Vito Palombella	Independent Director	4.1yrs	CHF125.00k	0.011% CHF 11.7k
Agnete Fredriksen	Independent Director	3.1yrs	CHF125.00k	sin datos
Michael Vasconcelles	Independent Director	4.1yrs	CHF135.00k	0.011% CHF 11.7k
Sandip Kapadia	Independent Director	4.1yrs	CHF130.00k	0.011% CHF 11.7k
Dominik Hochli	Independent Director	3.1yrs	CHF133.00k	sin datos

4.1yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de 0QXX se considera experimentada (4 años de antigüedad promedio).

Molecular Partners Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG Announces Executive Changes

High number of new directors

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

High number of new directors

Recent updates

Insufficient new directors

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Full year 2023 earnings released: CHF1.89 loss per share (vs CHF3.63 profit in FY 2022)

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Third quarter 2023 earnings released: CHF0.35 loss per share (vs CHF0.41 loss in 3Q 2022)

Molecular Partners AG Announces Executive Changes

Second quarter 2023 earnings released: CHF0.49 loss per share (vs CHF0.14 loss in 2Q 2022)

First quarter 2023 earnings released: CHF0.45 loss per share (vs CHF4.74 profit in 1Q 2022)

Full year 2022 earnings released: EPS: CHF3.63 (vs CHF2.06 loss in FY 2021)

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia

Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

High number of new directors

Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors

Third quarter 2022 earnings released: CHF0.41 loss per share (vs CHF0.38 loss in 3Q 2021)

Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Second quarter 2022 earnings released: CHF0.14 loss per share (vs CHF0.56 loss in 2Q 2021)

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Johnson Fistel Files A Class Action Complain Against Molecular Partners AG

Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2

Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – Moln

First quarter 2022 earnings released: EPS: CHF4.74 (vs CHF0.57 loss in 1Q 2021)

High number of new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19

Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients

Third quarter 2021 earnings released: CHF0.38 loss per share (vs CHF0.67 loss in 3Q 2020)

Forecast to breakeven in 2022

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Second quarter 2021 earnings released: CHF0.56 loss per share (vs CHF0.52 loss in 2Q 2020)

Forecast to breakeven in 2021

Novartis and Molecular Partners Announce Start of EMPATHY Clinical Trial for ensovibep for the Treatment of COVID-19

Director has left the company

New 90-day low: CHF20.65

Revenue misses expectations

Full year 2020 earnings released: CHF2.51 loss per share (vs CHF1.70 loss in FY 2019)

Full year 2020 earnings released

Revenue misses expectations

New 90-day high: CHF23.25

Molecular Partners AG to Report Fiscal Year 2020 Results on Feb 26, 2021

New 90-day high: CHF25.20

New 90-day high: CHF25.20

New 90-day high: CHF25.20

Novartis AG (SWX:NOVN) acquired 6% stake in Molecular Partners AG (SWX:MOLN) for CHF 30 million.

Novartis Announces Collaboration with Molecular Partners AG to Develop Two DARPin® Therapies Designed for Potential Use Against COVID-19

New 90-day low: CHF15.60

Earnings released

Molecular Partners AG to Report Q1, 2021 Results on May 12, 2021

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad